Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer

NCT00086827 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

Recurrent Small Cell Lung Cancer

Interventions

DRUG: romidepsin
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)